{"disease":{"id":"hyperlipidemia","name":"hyperlipidemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":27,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"fluvastatin-sodium","indication_name":"Reduce LDL-C in Primary Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUVASTATIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis."},{"drug_id":"caduet","indication_name":"Primary Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"inositol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"nicotinic-acid","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"nicotinic-acid","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ciprofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipanor","generic_name":"CIPROFIBRATE","company_name":"Winthrop Pharmaceuticals UK Limited","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"ciprofibrate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"ezetrol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"ezetrol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"levothyroxine-sodium","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unithroid","generic_name":"LEVOTHYROXINE SODIUM","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"l-Thyroxine","quality_score":70,"revenue":null,"mechanism":"Unithroid works by replacing or supplementing the thyroid hormone thyroxine, which is produced by the thyroid gland."},{"drug_id":"fluvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"colestilan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colestimide","generic_name":"colestilan","company_name":"Tanabe Pharma Corporation","drug_phase":"discontinued","molecular_target":"","drug_class":"colestilan","quality_score":0,"revenue":null,"mechanism":"Colestimide works by inhibiting the absorption of cholesterol and/or phosphorus in the intestines."},{"drug_id":"dextrothyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choloxin","generic_name":"DEXTROTHYROXINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor","drug_class":"dextrothyroxine","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"nicomol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cholexamin","generic_name":"NICOMOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"nicomol","quality_score":null,"revenue":null,"mechanism":"Cholexamin works by inhibiting the enzyme responsible for cholesterol synthesis."},{"drug_id":"colestipol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colestid","generic_name":"Colestipol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type V hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"ezetimibe","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetimibe","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"probucol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorelco","generic_name":"PROBUCOL","company_name":"","drug_phase":"marketed","molecular_target":"Serine protease hepsin","drug_class":"probucol","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"livalo","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livalo","company_name":"Kowa Research Institute, Inc.","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"levothyroxin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"levothyroxin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"thyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thyroxine","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vascepa","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vascepa","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Diacylglycerol O-acyltransferase 1","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"colextran","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dextran 2-(Diethylamino)Ethyl Ether","generic_name":"COLEXTRAN","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"colextran","quality_score":null,"revenue":null,"mechanism":"Colextran works by binding to and removing excess cholesterol from the bloodstream."},{"drug_id":"cholestyramine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"myoinositol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"levothyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synthroid","generic_name":"levothyroxine","company_name":"Generic (originally multiple — AbbVie/Synthroid)","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"Thyroid hormone","quality_score":10,"revenue":null,"mechanism":"Synthetic thyroxine (T4) that replaces deficient thyroid hormone, restoring normal metabolism, growth, and development."},{"drug_id":"niacin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"niacin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nicotinyl-alcohol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyridylcarbinol","generic_name":"nicotinyl alcohol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"nicotinyl alcohol","quality_score":null,"revenue":null,"mechanism":"Pyridylcarbinol works by providing the body with a precursor to NAD+, a crucial coenzyme involved in energy metabolism."},{"drug_id":"fenofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"fenofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"clofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipavil","generic_name":"CLOFIBRATE","company_name":"","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"clofibrate","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"olmesartan","indication_name":"hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"bezafibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Befizal","generic_name":"BEZAFIBRATE","company_name":"","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"bezafibrate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hctz","indication_name":"hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"icosapent-ethyl","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vascepa","generic_name":"ICOSAPENT ETHYL","company_name":"Amarin Pharms","drug_phase":"marketed","molecular_target":"Diacylglycerol O-acyltransferase 1","drug_class":"icosapent ethyl","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pitavastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livalo","generic_name":"PITAVASTATIN","company_name":"Kowa Co","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cerivastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baycol","generic_name":"CERIVASTATIN","company_name":"Bayer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"cerivastatin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"aprocitentan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tryvio","generic_name":"APROCITENTAN","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure."},{"drug_id":"lovastatin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"chembl-chembl1496","indication_name":"Reduce LDL-C in primary hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ROSUVASTATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"lovastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."}],"pipeline":[],"offLabel":[],"totalMarketed":51,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06338956","title":"Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":135877,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06903897","title":"Social Needs Screening and Chronic Diseases Study (WE CARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT03065543","title":"Hyperlipidemia Therapy TERCET Zabrze Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":25000,"lead_sponsor_name":"Silesian Centre for Heart Diseases","has_results":false},{"nct_id":"NCT03862183","title":"Hospital-level Variation in the Management of Blood Pressure and Low-density Lipoprotein in the Outpatient Hypertensives in China-a Cross Sectional Study","phase":"","overall_status":"UNKNOWN","enrollment_count":21000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT02285166","title":"Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3","phase":"","overall_status":"COMPLETED","enrollment_count":15330,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04118348","title":"Evaluating the Efficacy of Pediatric Lipid Screening Alerts","phase":"NA","overall_status":"COMPLETED","enrollment_count":13340,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT03973931","title":"Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications","phase":"NA","overall_status":"COMPLETED","enrollment_count":9501,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT01420016","title":"Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk","phase":"NA","overall_status":"COMPLETED","enrollment_count":7914,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT06543706","title":"Metabolic Syndrome and Related Diseases in Healthcare Workers","phase":"","overall_status":"COMPLETED","enrollment_count":7432,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT02991534","title":"Cardiovascular Risk Screening and Risk Reduction in Women Vets","phase":"NA","overall_status":"COMPLETED","enrollment_count":6009,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT03748420","title":"Medication Adherence Clinical Decision Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":5421,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT06831162","title":"Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4809,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT03329729","title":"PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT","phase":"","overall_status":"COMPLETED","enrollment_count":4700,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT01854918","title":"Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3681,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02153073","title":"Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters","phase":"","overall_status":"COMPLETED","enrollment_count":3084,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05411887","title":"Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2845,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT00289900","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2340,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01968967","title":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2139,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01763866","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2067,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06694012","title":"Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Osaka Metropolitan University","has_results":false},{"nct_id":"NCT07180368","title":"Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT06022575","title":"Telehealth Integrated Care Model in Patients With Cardiometabolic Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":1302,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05457582","title":"PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI","phase":"NA","overall_status":"RECRUITING","enrollment_count":1212,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT04660630","title":"A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1172,"lead_sponsor_name":"Beijing Chao Yang Hospital","has_results":false},{"nct_id":"NCT06951451","title":"Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sultan Qaboos University","has_results":false},{"nct_id":"NCT07311941","title":"Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04398771","title":"To Evaluate Safety and Effectiveness of RovatitanTab.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT05242055","title":"Integrated Diagnosis and Treatment of CKD on Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT02662569","title":"Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":986,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07216482","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":975,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07273513","title":"\"Smart Family Doctor\" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":951,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT07421284","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT02433288","title":"Rosuvastatin Adherence App Study in China","phase":"NA","overall_status":"COMPLETED","enrollment_count":885,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07421297","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT00001154","title":"Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT02100514","title":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":746,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06094491","title":"Virtual Diabetes Group Visits Across Health Systems","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":720,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT07253584","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04885218","title":"Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":692,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01380730","title":"LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00941603","title":"Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":619,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07295418","title":"A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":618,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT01763827","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03947866","title":"Ezetimibe-Rosuvastatin Evaluation Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT00308386","title":"DYNAMIC Study: (Diabetes Nurse Case Management And Motivational Interviewing for Change)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":false},{"nct_id":"NCT02913794","title":"Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control","phase":"","overall_status":"COMPLETED","enrollment_count":541,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06615609","title":"\"Smart Family Doctor\" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":536,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT01984424","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07444086","title":"QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":510,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}